This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk07: Good morning, everyone, and welcome to the Staris PLC fourth quarter 2021 conference call. All participants will be in a listen-only mode. Should you need assistance, please see a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star and then one using a touch-tone telephone. To withdraw your questions, you may press star and two. Please also note today's event is being recorded, and at this time, I'd like to turn the conference call over to Julie Winter, Investor Relations. Ma'am, please go ahead.
spk00: Thank you, Jamie, and good morning, everyone. Speaking on today's call, we have Mike Tokich, our Senior Vice President and CFO, Walt Rosebrough, our President and CEO, and Dan Crestillo, our Chief Operating Officer. I do have a few words of caution before we open for comments. This webcast contains time-sensitive information that is accurate only as of today. Any redistribution, retransmission, or rebroadcast of this call without the express written consent of Staris is strictly prohibited. Some of the statements made during this review are, or may be considered, forward-looking statements. Many important factors could cause actual results to differ materially from those in the forward-looking statements, including, without limitation, those risk factors described in Staris' securities filings. The company does not undertake to update or revise any forward-looking statements as a result of new information or future events or developments. Staris' SEC filings are available through the company and on our website. In addition, on today's call, non-GAAP financial measures including adjusted earnings per diluted share, adjusted operating income, constant currency organic revenue, and free cash flow will be used. Additional information regarding these measures, including definitions, is available in today's release. This also includes reconciliations between GAAP and non-GAAP financial measures. Non-GAAP financial measures are presented during this call with the intent of providing greater transparency for supplemental financial information used by management and the Board of Directors in their financial analysis and operational decision-making. With those cautions, I will hand the call over to Mike.
spk04: Thank you, Julie, and good morning, everyone. It is once again my pleasure to be with you this morning to review the highlights of our fourth quarter performance. For the quarter, constant currency organic revenue increased 0.3% as favorable pricing was somewhat offset by organic volume, which was slightly lower than last year's strong pre-COVID performance. Key Surgical added $32 million to revenue in the quarter, which is somewhat lower than we originally anticipated due to continued disruption of COVID-19. You will notice that we have a small acquisition called out within AST. In January, we completed the acquisition of one of our suppliers. While this is a vertical integration, we do expect revenue generation of approximately $25 million annually. Gross margin for the quarter was flat with the prior year at 44.3% as favorable pricing and cost management were offset by mix and currency. EBIT margin for the quarter was 22.3% of revenue, an increase of 60 basis points from last year. The adjusted effective tax rate in the quarter was 25% and 20.7% for the full fiscal year, higher than last year and higher than our expectations due to income mix from higher tax rate countries and discrete item adjustments, including stock compensation. As we noted in the release this morning, we have discontinued the use of LIFO. We believe that the FIFO method of accounting is preferable because it more closely resembles the physical flow of our inventory, aligns how we manage the business, and improves comparability to other companies. Net income in the quarter was flat at $140.3 million, and earnings per share were $1.63 million. Our balance sheet is a continued source of strength for the company. Our leverage ratio at the end of the fourth quarter is below 1.9 times as we continue to pay down debt post the key surgical acquisition. Considering our cash position of $220 million, access to available credit lines, and a low leverage ratio, we are well positioned from a liquidity standpoint. Following the close of Cantel Medical, we expect our leverage ratio to be about three times as we take advantage of the financing arrangements already put in place, including our first-ever public debt offering. During the fourth quarter, capital expenditures totaled $74.8 million, while depreciation and amortization was $59 million. Free cash flow for fiscal 21 was strong at $450.9 million, an increase of approximately $70 million over last year, primarily due to working capital improvements somewhat offset by higher capital expenditures. With that, I'll turn the call over to Walt for his remarks.
spk03: Thanks, Mike. Good morning, everyone, and thank you for joining us today. Mike has already discussed the quarter, so I will focus on the full year and then turn the call to Dan to discuss our outlook for fiscal 22. Looking back on FY21, Steris fared better than our most positive expectations at the beginning of this unprecedented time in our history. The commitment of our people and the resilience of our businesses allowed us to weather this storm in a positive manner. Remarkably, our revenue was up somewhat in fiscal 2021 as our existing business was stable in total while we completed acquisitions that added to our growth for the year. Our net income and free cash flow both improved double digits as we managed costs and working capital across the business. From a segment perspective, our life science business had another very strong year, growing constant currency organic revenue 11% as our biopharma customers used our consumables and ordered a record amount of capital equipment. Our AST segment also had a very good year, ending up 7% on a constant currency organic revenue basis, despite a slow start due to the global decline in healthcare procedure volumes. While global procedures are not yet back to pre-COVID levels, AST was able to grow as the year progressed because our previous capacity expansions allowed us to process single-use products related to COVID treatment, testing, and vaccine production. As procedure volumes began to recover in the second half and core medical device customers increased manufacturing, AST has returned to more historic growth rates. Our healthcare business was clearly the most impacted by the pandemic and the related decline in procedure volumes, with constant currency organic revenue down 4% for the year. By the end of the fiscal year, our consumables were trending up nicely in line with procedures And capital equipment orders were very strong, leading to a record year-end backlog of over $200 million. Our R&D teams have done a great job updating our offerings across our healthcare business the past year or so. With the addition of Key Surgical and Cantel products and services, along with Steris' portfolio, we will be better positioned than ever to meet the needs of our customers going forward. The strength of our balance sheet allowed us to operate almost normally last year, increasing our dividend, investing in R&D and capital spending opportunities in all our current businesses, not laying off any of our people for COVID-related volume reductions, completing the acquisition of Key Surgical in November, and executing the merger agreement with Cantel Medical. We believe these long-term oriented actions will propel future revenue and profitability growth across our business. In support of the Cantel transaction, our people achieved another significant milestone when we completed our first public debt offering. This was after securing investment grade ratings on our maiden voyage with all three rating agencies. Once the Cantell deal closes and that debt is on our books, we are committed to reducing our leverage to continue to justify those strong ratings. We expect the strength of our balance sheet to remain a hallmark of our company going forward. All in all, considering the additional issues required by the pandemic, a tremendous set of achievements for Sterist this past year. As you might expect, This is my final Steris earnings call. As I shift to my new role as an advisor to management and the board, I am very pleased to hand the reins to Dan Carestio, who will succeed me as president and CEO. Dan is a veteran senior executive of our company, having spent more than two decades at Steris with increasing responsible leadership roles. He knows the business. He's fortunate to be supported by an outstanding senior management team. most of whom have also been with our company for a decade or more of success. I am confident that our company is in very good hands with Dan and this Steris leadership team. I want to take a moment also to recognize our analysts. Several of you have been with us for many years. Chris for 12, Larry for nine, Dave and Matt seven years each. Mike and Mike have picked up coverage fairly recently, and we certainly value their addition. We appreciate all of your efforts on behalf of your clients and our long-term shareholders. And it has been my absolute pleasure to work with each of you this past decade or so. In closing, I would like to thank the people of Steris for making our company what it is today, and better yet, what it will be tomorrow. The 13,000 people working every day in pursuit of our mission, soon to be over 16,000, are what make the company tick. I also greatly appreciate our board members of the last 14 years. I've been blessed to work with and for a talented and diverse board, and two wonderful chairmen in Jack Wareham and now Mohsen Sohi. This board's guidance will continue to help Dan and the team move ever forward. And I'm tremendously grateful to all of our long-term shareholders who have believed in the value our company provides to our customers, our people, and our shareholders. It's been my honor and pleasure to serve as CEO of this great company for nearly 14 years, and I look forward to its continued successes. I am absolutely confident that the best is yet to come, as you will hear next from Dan while reviewing our outlook. Mr. Crestio.
spk05: Thanks, Walt. I want to echo Walt and Mike's welcome to all of you. We really appreciate you taking the time to join us today. As Walt discussed, Stairs had a great year in fiscal 2021, all things considered. and we remain very excited about what is yet to come. Not only do we expect a nice rebound in our base business in fiscal 2022, but we look forward to bringing together three great companies, Steris, Key Surgical, and soon, Cantel. That does, however, make modeling of Steris a bit more difficult for all of you, so I will focus my comments today on our overall outlook. and then walk you through our expectations for the new fiscal year. Including acquisitions, we expect total revenue of approximately $4.5 billion. That assumes 10 months of inorganic revenue from Cantel, the remaining seven months of Key Surgical before anniversaries, along with smaller AST supplier as inorganic contributors. It also assumes about $15 million favorability from foreign currency. Underlying that growth will be constant currency organic revenue growth of 8% to 9% for legacy Steris. That growth rate will be driven by significant rebound in our healthcare segment, the ongoing success of AST, and lower than normal growth versus comparisons to fiscal 2021's very strong performance for the life sciences segment. Before moving on to profitability, I wanted to take a moment to discuss the upcoming changes to our segments following the completion of the Cantel acquisition. Today, Cantel has four major businesses, medical, dental, life sciences, and dialysis. Medical and dialysis will become part of Steris' healthcare segment As we have said previously, we anticipate that dental will be its own segment. To more closely align with Steris' customers, we will split Cantel's life sciences business with the renal business, about 85% of their revenue going to our healthcare segment and the balance going to our life science segment. From a total revenue split perspective, The net impact of all these moves will leave us with the following segment breakdown. Health care, 63% of revenue. AST, 17% of revenue. Life sciences, 11% of revenue. And dental, 9% of revenue. Operating margins are expected to improve, but they will be tempered a bit as we expect operating expenses such as travel and sales and marketing to come back closer to normal, in particular in the second half of the year. We continue to believe that the cost synergies of $110 million are achievable for Cantel, with about 50% of that total recognized in the first 24 months. Our fiscal 2022 outlook includes approximately $25 million of these cost synergies. Adjusted earnings per diluted share are anticipated to be in the range of $7.40 to $7.65, which assumes an adjusted effective tax rate of 21 to 22% and a share count of approximately 99 million diluted shares. This share count assumes that Cantel's convertible notes are converted and settled in cash. We would expect stronger revenue in the second half of our fiscal year with earnings in line with our traditional 45-55 split. From a balance sheet perspective, as Mike discussed, our leverage will initially be a bit higher than normal for Staris following the close of Cantel. We have committed to debt repayment as a priority over the next couple years and would expect to be back closer to our normal sweet spot in the mid twos within that timeframe. As Steris continues to invest in AST facility expansions and outsourced reprocessing centers and assuming about $50 million of CapEx for Cantel, our total capital spending is anticipated to be approximately $320 million in fiscal 2022. Free cash flow will be impacted by the integration and deal-related costs of approximately $200 million and in total is anticipated to be approximately $380 million. You will recall that we do not adjust free cash flow for deal integration costs. Other than focusing on repaying debt, our capital spending priorities will be the same. Dividends, investing in our current businesses, tuck in M&A, and share buybacks. We are confident we have the cash generation capacity to invest appropriately in our growth priorities and reduce our debt in the coming years. I would be remiss if I did not take this opportunity to thank Walt today. Walt has been a mentor to me and the rest of the Steris leadership team for many years, and I would not be prepared to step into the CEO role without his support and counsel over these past years. Thank you, Walt, for everything you've done to get Steris where we are today, a great company, consistently improving to meet the needs that are evolving for our customers, staffed by associates who have safe and rewarding work, and generating above-market returns for our investors as they have come to expect. With that, I will turn the call back over to Julie to open up for Q&A. Julie?
spk00: Thanks, everyone, for your comments. Jamie, if you could just give the instructions, we can get into Q&A.
spk07: Ladies and gentlemen, at this time, we'll begin the question and answer session. To ask a question, please press star and then 1 using a touch-tone telephone. If you are using a speakerphone, we ask that you please pick up the handset before pressing the numbers to ensure the best sound quality. Once again, that is star and then one to join the question queue. If you do need to remove yourself from the queue, you may press star and two. Our first question today comes from Dave Tercalli from JMP Securities. Please go ahead with your question.
spk01: Great, thanks, and Walt, we'll certainly miss you. Time does fly. It's been a great run, though. Maybe I could just start with the guidance, the assumption. I know when you bought Cantel, you gave us a backwards look at EBIT contribution, but obviously that was kind of a year that had some special impact. So I was wondering if you might just talk a little bit about what that contribution you think that will be now. Obviously, the guide looks like there's some accretion in there from Cantel, and I'm just Curious if you might want to share some of the details around specifically that contribution.
spk04: Yeah, Dave, this is Mike. So obviously, if you look at our guidance, including Cantel, from an EBIT contribution standpoint, they'll have similar EBIT margins that Legacy Steris has. And that EBIT margin dollars will be right around $230, $240 million contribution for the 10 months
spk01: fiscal year 22 got it and maybe just as a quick follow-up uh you mentioned the debt congrats on the offering could you just tell us uh you know sort of what i guess the interest assumptions maybe either for the year i imagine you may pace them down as you go along but uh maybe sort of the aggregate amount of debt and and sort of the interest expense you expect to incur thanks a lot
spk04: Yes, certainly. So we did, as Walt and I both mentioned, we did do our first public debt offering for $1.35 billion. We did two tranches, a 10-year and a 30-year, split equally, so about $675 million each. That debt combined is about 3.225%. And then obviously the rest of the debt that we have will be between our private placements, term loans, and whatever we draw on our revolving credit facility. So what we are projecting is all in from a rate standpoint, about 2.5% for the year and just under $4 billion when we start with Cantel and we close Cantel. And then obviously we anticipate paying some of that down throughout the remainder of this fiscal year. And as Dan and I both mentioned, We have the mindset to get back into the low to mid twos sometime within the next few years.
spk07: Thank you. Our next question comes from Matthew Nishan from KeyBank. Please go ahead with your question.
spk06: Great. Thank you for taking the questions. Walt, we will definitely miss you and always appreciated your candor and insight. Thank you very much. Just to follow up on the modeling questions, are you still planning to bucket healthcare and life sciences with capital equipment, consumables, and service? And then as far as interest expense tax and share count, could you kind of break out the 1Q21 concept? or the first quarter contribution versus the full year given the mid-quarter close?
spk04: Yeah, so first of all, to answer your question about the segments, Matt, we are going to continue to report capital consumables and services or service for both healthcare and life sciences, and obviously services for just AST as we typically have done. The one factor that we are looking at is dental, is how to break that out. We know it's going to be a separate segment. We've got a little bit of work to do in order to figure out what particular breakout we want to go down there. They do have a lot of instruments, especially around the Hugh Freedy standpoint. So more to come on that. And then, Matt, I don't think we're going to get into that level of detail on the quarterly breakouts. You know, we're about 99 million employees. shares for the year. Obviously, Cantel's adding almost 15 million of those when we close. So that's about as much detail as I think we're going to give at this point.
spk06: Okay. And then just a question around Key Surgical. I think you had previously thought that the pluses and the minuses can even themselves out in that business from the disruption from COVID-19. Has anything kind of changed there? And for next year, does that grow in line with the company on an organic basis for Key Surgical?
spk05: Yeah, this is Dan, Matt. What I would say is the long-term view of key is still incredibly positive and they are highly procedurally driven. And if you recall, we'll be spoken before, they have much more opportunity in Europe, but they also complimentary have much more exposure in terms of COVID and COVID had a much more significant effect in the winter months in Europe than what we had initially anticipated. Now, as we continue to see recovery, both in the U.S. or North American market and the European markets, we're seeing the positive trends of Keat, and we're confident it'll come back to track with Steris as normal procedure rate-driven type businesses.
spk06: And then big picture, you've seen a couple of your competitors across your businesses go public, and previously more under the radar areas. Does that change the competitive landscape for you, or is it a validation of the opportunity in those areas? Yes.
spk05: It doesn't change anything in terms of competitive landscape, I would say.
spk07: Okay, thank you very much. Our next question comes from Mike Mattson from Needham & Company. Please go ahead with your question.
spk08: Hi, thanks for taking my questions, and Walt, congrats on the retirement. I know I've only covered the company about a year or so, but a joy to interacting with you over that time and learning about the company. So thanks. So I guess first, you know, I've tried to back into kind of what the guidance is implying for Cantal revenue on an annualized basis. It seems like it's around 1.1 billion. Again, that's for the full year. I know you're not going to have it in your numbers for the full year, but that's a little bit below. I think we're modeling around we were modeling around $1.2 billion. So it also sort of implies that flat growth from the prior sort of 12-month period. Is that right? And, you know, why aren't you assuming kind of better growth there if it is right?
spk05: It is right. That's what we're modeling now. You know, Cantel was a beneficiary of a lot of PPE sales, especially in the late summer, early fall months of this year, and those are Those were obviously pandemic driven and likely not to stick around. So we've appropriately removed any assumptions on high or continued sustained levels of PPE in the go forward model.
spk03: And relative to Steris, they are even more heavily procedurally driven and particularly elective procedures. Dental is largely an elective procedure space. And as a result, probably a little slower to come back in our thinking. But again, as Dan has mentioned, on key, we don't see any difference the long term of that. And it's very, very much like our modeling that we put in place when we did the deal.
spk08: Okay. Thanks. And then just on the transition from FIFO to FIFO, is there any kind of financial impact from that to EPS or cash flow or anything?
spk04: Yeah, Mike, there is, but it's not material at all. And going forward, LIFO has become a very small percentage of our inventory pool. So we did restate the quarters. Looking back, we will do the same thing and give more detail in the 10-K when we file it at the end of this month. But nothing material that I would say is going to change directionally. the company or the outlook for the company.
spk03: I think Mike mentioned it was $0.03 this past year. That gives you an order of magnitude. It's not a big deal.
spk08: Okay, got it. Sorry, I missed that. Thanks, guys.
spk07: Our next question comes from Chris Cooley from Stevens Incorporated. Please go ahead. It's been a true pleasure to get to you.
spk02: Can you hear me now? Yep. I'm sorry. Yes, good morning. Thanks for taking the questions, and Walt, I just want to say it's been a true pleasure to work with you these last 12 years. Your accomplishments here have been tremendous, and I wish you all the best going forward. Julie and Mike and Dan, y'all are stuck with me. Let's go for 13. My questions here this morning, if I may, I want to first start on the cash flow guide for the full year. It's impressive. You know, when we look at the 380, obviously inclusive of $200 million in charges, if we make kind of like that adjustment, you're looking at roughly 13% of the reported revenue guide. But, you know, when I think about that, help me kind of unpack what the underlying assumptions are when we think about the margin structure, because in this most recent quarter, On the core steris side, obviously you had a record operating margin contribution from AST. Life science tapered a little bit with the consumables coming down. Just want to try and make sure I'm understanding kind of what the underlying assumptions are there on getting to that 380 for the full year. And I have a quick follow-up. Thank you.
spk04: Yeah, yeah, certainly. Obviously, the deal-related and the integration costs, you know, the $200 million we're anticipating off of free cash flow, we are once again increasing our capex. pretty substantially, both not only on the STERA side, in particular for AST facility expansions, but also continued operating room or ORC expansions, reprocessing expansions within particularly North America. And then we do have about $50 million of CAPEX-identified specifically for Cantel Medical. But one of the things that we continue to see, and Dan talked about it a little bit, is on an income standpoint, We are anticipating that both travel, sales, and marketing will be up significantly year over year. In addition, R&D, continued R&D spend, will also increase. So that's definitely going to have an impact not only on the net income side but also on the free cash flow standpoint. And then the other thing, we've done a really nice job on this year, is improving and driving improvements in working capital. And we continue to think that we can do that. and then obviously I think there's some opportunity longer term with Cantel on a standalone basis to drive that, but that's going to take us a little bit of time as we integrate the companies to get those benefits, Chris.
spk05: Yeah, you know, Mike, one other comment too on that is we built an awful lot of inventory this year just for our fears around supply chain assurity and things like that, and we're still sitting on an awful lot of that inventory, and as As we are optimistic that supply chains will get better in the next six months, we'll probably go back to our more leaner mindset in terms of inventory management, but an abundance of caution not to stock out for our customers. We've been running a little heavier than normal.
spk02: Makes sense, and I appreciate all the color there. And then just lastly for me, when I think about just maybe bigger picture looking at the integration going forward, obviously rolling in Key Surgical and about to close here on the Cantel acquisition. When we look at the guide, there seems to be some changes versus the last kind of major acquisition the company did, and I'm thinking back to Synergy. When we think about the related contribution from growth and similarly from margin, Help me just think a little bit, though, about kind of how you're approaching this, kind of where you see the kind of key milestones. And also, I think it's maybe getting lost a little bit here this morning, but you did step up the Coursera's organic guide versus kind of what we've historically seen here. Help us kind of think about, again, what what you see there implicit in the guide and what's a little bit different this time when you're doing the integration versus Synergy. I realize they're different businesses, but just trying to think a little bit about where the challenges lie and where you have added confidence. Thanks so much. And again, Walt, all the best.
spk05: Yeah. Chris, what I would say is it's a very different deal than what we talked about. And Synergy was more of a complimentary revenue play opportunity with a little bit of cost out. because they were largely present in Europe where we had less presence, and there wasn't much overlap between the two. In the case of Cantel, there is significant cost-out opportunity. That's why we've identified the $110 million target that we're going after. And a lot of that is in some of the leadership compensation and sort of where we have redundancy amongst executives and folks within the organization. So we're actively working on day one now, if you will, all the messaging, all the mapping of who's reporting to who and getting the structures aligned and working with the Cantel teams to get there. So that's the difference between the two deals in terms of where we are. And we do believe there's probably going to be some revenue synergies out of the complimentary portfolio offering, but clearly we're focused on the cost out piece early on. In terms of the other question I think around the margins, we do believe as procedures come back to normal, that will continue to drive growth in our AST business and in our reoccurring revenue consumables businesses, especially in the healthcare segment, which tend to be higher margin consumable type annuity businesses. And we do think that as we get back to pre-COVID levels in the back half of our fiscal year, we'll see a significant benefit from that in our overall margin structure.
spk03: Chris, I would add just a comment on that, the same thing Dan talked about. This being a much more cost-out type of a deal, first of all, we're fortunate in that, I mean, I use the word fortunate in kind of an odd way, COVID caused both of us to put hiring freezes across much of the company. And so a big piece of those cost synergies are going to be handled by not hiring people that one or both of us would have hired because we have people from the two companies. So a piece of this will go easier than normal. We haven't built that into our model in terms of the cost of synergies. We've included what I call our normal cost of synergies. We could get a break on that, depending on how that works out. Unfortunately, people have to be in the right place at the right time in their career and all those things. But I think that's a real opportunity for us. And we're quite good about using people and not laying people off just to hire somebody else. And so I think that's a real positive. And then the second component is if you look at our history, We eventually get our revenue synergies. We always get our cost synergies. And so if I were a betting person on Mr. Crest, you on Mr. Tokic being able to get $110 million, I'd take the bet all day long for as big a bet you want to make.
spk07: Thank you. Once again, if you would like to ask a question, please press star and then 1. To withdraw your questions, you may press star and 2. Our next question comes from Michael Pollard from Baird. Please go ahead with your question.
spk09: Hey, good morning. Thank you for taking the question. I have a couple. We'll follow the synergy thread there. I'm curious, the $200 million of deal and integration-related expenses this year, can you help frame the potential tail to that into the next fiscal year? And within the $200 million, what portion of that do you consider truly profitable? one-time and deal-related consulting legal transaction expenses, and what portion of that is investment you're making to capture the guided cost synergies?
spk04: Yeah, Mike. So, I mean, I would say that You know, IRMAT, they're fairly equal, $100 and $100 million. $100 million to obtain cost synergies, and then $100 million for the costs of the deal-related, obviously, the attorney's fees, the banker's fees, the accountant's fees, the banks themselves going through everything we've done from a financing standpoint. So those are about equal. The bulk of the deal costs should be done, obviously, this fiscal year would be our guess. And we'll have a little bit of a tail as we continue to gain some synergies, cost synergies. We'll have to pay for that. Remember, our mindset was when we did the announcement and our assumptions were in order to obtain that $110 million of cost synergies, it was going to cost us about one for one from a cost standpoint to attain those synergies. So that's what that $200 million represents.
spk09: God, it's just scribbling down notes here. That's fine. Yeah, thank you for that, Mike. The comment on ORC as an influence on the CapEx step-up caught my ear. I know it's a small piece of the business. I don't hear a ton about it, but I'd imagine you're not putting dollars into the ground and hoping customers come. So are there wins there to talk about that are driving the CapEx comment for ORCs?
spk05: This is Dan, Michael. I would say they're not. They're not material in terms of the broader picture of Staris, but it does cost some capital. It's similar to an AST-type location in that there is a startup ramp-up period where it may be initially a bit dilutive until the volume grows. But, no, we build those not on speculation but on relationship and contracts with our customers. And we are very confident that when we're putting brick and mortar in the ground that we're in a market with committed contracts and customers.
spk09: Yes. Three more quick ones, I promise. The AST supplier acquisition, supplier of what?
spk05: Oh, they make our e-beam and x-ray equipment and conveyance systems and control systems for the non-isotope radiation.
spk09: Helpful. What's the latest thinking on the vaccine as a catalyst in life sciences? You know, the equipment number was quite strong in the quarter. I continue to overmodel the consumables piece. And so, you know, as we sit here with the U.S. vaccination progress demonstrable, you know, mid-May, the world's catching up or XUS is catching up. Like, you know, what's the vibe there? What's your view on that? near-term sequential direction of some of those numbers within Life Sciences?
spk05: Yeah, you know, I'll go back to what we've talked about in the past, and, you know, we got a lift on COVID in Life Sciences consumables, but much of it was pre-buying from our customers. It wasn't necessarily attributed to COVID vaccine demand. There was some, I mean, and we did get some tailwinds from it, but really it was the buy-ahead on products that weren't necessarily relative to COVID vaccine manufacturing. Now, we do think that it did have some positive impact on our capital equipment business, and we saw a number of units sold into Asia in particular that were specifically for vaccine-type startup facilities that they were putting up quickly. Yeah, long-term, it's not a negative, I can tell you that. But you're not going to see, you know, I would assume we've hit the plateau off the peak and we'll, you know, we'll modestly grow from there as opposed to continuing to grow off of the trajectory that we expected to see as it relates specifically to COVID vaccines.
spk03: Yep. But Dan's modestly grow. It is our fastest growing business. Modestly grow as it relates to being a life science business that does consumables. That's right.
spk09: Last one, I promise, probably for Mike. So a couple of questions on the debt and interest expense. So appreciate the comments so far. My question is really narrow. For the June quarter, I think you put this debt in place at the very beginning of this quarter. Correct me if I'm wrong on that, called April 1, give or take. I was looking through the prior press releases. For the reporting of adjusted EPS, are you going to exclude the interest expense related to the financing until the Cantel deal closes, or would we expect a full quarter of interest expense in this June quarter?
spk04: No, Michael, you're right. We did put that financing in place in April so that it is in FY22, and we will not be adjusting any of that out. Obviously, it's a two-month overhang, if you will. for putting that in place. So you should expect a full year of the higher interest expense for the Cantel acquisition.
spk09: All right. Thank you very much.
spk04: You're welcome.
spk07: And ladies and gentlemen, in showing no additional questions, I'd like to turn the floor back over to the management team for any closing remarks.
spk00: Thanks, Jamie, and thanks, everybody, for taking the time to join us. We look forward to catching up with many of you in the coming days.
spk07: And ladies and gentlemen, with that, we'll conclude today's conference call. We do thank you for attending today's presentation. You may now disconnect your lines.
Disclaimer